Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype

Breast Cancer Research and Treatment

Volumn 67, Issue 1, 2001, Pages 61-70

  Milde Langosch, Karin ^a   Bamberger, Ana Maria ^a   Rieck, Gabriele ^a   Kelp, Bianca ^a   Löning, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; Immunohistochemistry; p16; Rb; Western blots

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P16;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DENSITOMETRY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ONCOGENE NEU; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RETINOBLASTOMA PROTEIN;

EID: 0034895071     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010623308275     Document Type: Article

References (19)

1. The p16INK4a/CDKN2A tumor suppressor and its relatives
2. Analysis of p16 gene deletion and point mutation in breast carcinoma
3. Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer
4. Antiprogestin inhibition of cell cycle progression in T47-D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21
5. Preferential loss of expression of p16 (INK4a) rather than p19(ARF) in breast cancer
6. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
7. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue
8. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines
9. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histological parameters
10. Expression pattern of the AP-1 family in breast cancer: Association of fosB expression with a well-differentiated, receptor-positive phenotype
11. p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors
12. P16/MTS1 and pRb expression in endometrial carcinomas
13. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation
14. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
15. INK4a messenger RNA is a marker of poor prognosis
16. High frequency of aberrant p16 INK4A expression in human breast cancer
17. Transcriptional regulation of the CDK inhibitor p16INK4a gene by a novel pRb-associated repressor, RBAR1
18. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells
19. Cyclin E, a redundant cyclin in breast cancer